Iterum Therapeutics receives Nasdaq delisting notice; shares to suspend Mar 5, 2026

Iterum Therapeutics plc

Received delisting determination letter on Feb 24, 2026 for failing minimum bid price of $1.00 per share.
Trading suspension on Nasdaq effective March 5, 2026 unless hearing requested before Nasdaq Hearings Panel.
Company evaluating appeal and strategic alternatives including possible wind-down or bankruptcy.
Also noncompliant with $35M minimum market value of listed securities and other listing standards.
Warns shareholders are unlikely to receive any meaningful distribution in a potential dissolution.

item 3.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-085646
form_type: 8-K
ticker: ITRMF
cik: 0001659323
company_name: Iterum Therapeutics plc
filed_at: 2026-03-02T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.790622+00:00
generated_at: 2026-05-15T22:40:41.066991+00:00
sec_items: ["3.01"]
event_type: other_material
sentiment: negative
materiality_score: 0.95
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-085646
json_url: https://secwatch.observer/filing/0001193125-26-085646.json
markdown_url: https://secwatch.observer/filing/0001193125-26-085646.md
text_url: https://secwatch.observer/filing/0001193125-26-085646.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1659323/000119312526085646/0001193125-26-085646-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1659323/000119312526085646/itrm-20260224.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-085646

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.